Oncomed Pharmaceuticals (OMED) & Its Rivals Critical Analysis
Oncomed Pharmaceuticals (NASDAQ: OMED) is one of 186 public companies in the “Biotechnology & Medical Research” industry, but how does it weigh in compared to its peers? We will compare Oncomed Pharmaceuticals to similar businesses based on the strength of its risk, dividends, earnings, profitability, valuation, analyst recommendations and institutional ownership.
Institutional and Insider Ownership
39.4% of Oncomed Pharmaceuticals shares are held by institutional investors. Comparatively, 49.3% of shares of all “Biotechnology & Medical Research” companies are held by institutional investors. 32.8% of Oncomed Pharmaceuticals shares are held by company insiders. Comparatively, 14.7% of shares of all “Biotechnology & Medical Research” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
This is a breakdown of recent ratings and target prices for Oncomed Pharmaceuticals and its peers, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Oncomed Pharmaceuticals Competitors||534||2380||6575||125||2.65|
Oncomed Pharmaceuticals presently has a consensus target price of $6.00, suggesting a potential upside of 53.06%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 23.21%. Given Oncomed Pharmaceuticals’ higher probable upside, research analysts clearly believe Oncomed Pharmaceuticals is more favorable than its peers.
This table compares Oncomed Pharmaceuticals and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Oncomed Pharmaceuticals Competitors||-3,342.37%||-543.52%||-39.97%|
Earnings & Valuation
This table compares Oncomed Pharmaceuticals and its peers gross revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Oncomed Pharmaceuticals||$25.15 million||-$103.10 million||-2.07|
|Oncomed Pharmaceuticals Competitors||$217.29 million||-$39.39 million||-93.21|
Oncomed Pharmaceuticals’ peers have higher revenue and earnings than Oncomed Pharmaceuticals. Oncomed Pharmaceuticals is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
Volatility & Risk
Oncomed Pharmaceuticals has a beta of 2.8, meaning that its stock price is 180% more volatile than the S&P 500. Comparatively, Oncomed Pharmaceuticals’ peers have a beta of 1.55, meaning that their average stock price is 55% more volatile than the S&P 500.
Oncomed Pharmaceuticals peers beat Oncomed Pharmaceuticals on 7 of the 12 factors compared.
About Oncomed Pharmaceuticals
OncoMed Pharmaceuticals, Inc. (OncoMed) is a clinical-stage biopharmaceutical company. The Company focuses on discovering and developing therapeutics that address the fundamental biology driving cancer’s growth, resistance, recurrence and metastasis. The Company’s therapeutic candidates and preclinical programs include Demcizumab (Anti-DLL4, OMP-21M18), Tarextumab (Anti-Notch2/3, OMP-59R5), Vantictumab (anti-Fzd7, OMP-18R5), Ipafricept (Fzd8-Fc, OMP-54F28), Brontictuzumab (Anti-Notch1, OMP-52M51), Navicixizumab (Anti-DLL4/VEGF Bispecific, OMP-305B83), Anti-RSPO3 (OMP-131R10), Anti-TIGIT (OMP-313M32) and GITRL-Fc trimer (OMP-336B11). Demcizumab is a humanized monoclonal antibody that inhibits Delta-like Ligand 4 (DLL4) in the Notch signaling pathway. Tarextumab is a human monoclonal antibody that binds to both the Notch2 and Notch3 receptors.
Receive News & Ratings for Oncomed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncomed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.